Keros Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Keros Therapeutics Inc KROS.OQ reported a quarterly adjusted loss of $1.14​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.34. The mean expectation of fourteen analysts for the quarter was for a loss of 98 cents per share. Wall Street expected results to range from $-1.63 to $3.49 per share.

• Revenue rose 2,027.3% to $3.04 million from a year ago; analysts expected $15.42 million.

• Keros Therapeutics Inc's reported EPS for the quarter was a loss of $1.14​.

• The company reported a quarterly loss of $46.03 million.

• Keros Therapeutics Inc shares had fallen by 31.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 30.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Keros Therapeutics Inc is $30.00

This summary was machine generated from LSEG data February 26 at 09:57 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)